Beneficial effects of pioglitazone on left ventricular hypertrophy in genetically hypertensive rats

Hypertension Research

Volumn 30, Issue 9, 2007, Pages 863-873

  Shinzato, Tomoko ^a   Ohya, Yusuke ^a   Nakamoto, Minori ^a   Ishida, Akio ^a   Takishita, Shuichi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Left ventricular hypertrophy; Myofibroblast; Peroxisome proliferator activated receptor ; Spontaneously hypertensive rat; Thiazolidinedione

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; GELATINASE A; GELATINASE B; GLUCOSE; INSULIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ECHOCARDIOGRAPHY; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; GENETICALLY HYPERTENSIVE RAT; GLUCOSE BLOOD LEVEL; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HISTOLOGY; INSULIN BLOOD LEVEL; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WISTAR KYOTO RAT; ZYMOGRAPHY;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; COLLAGEN TYPE I; COLLAGEN TYPE III; ECHOCARDIOGRAPHY; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; HYPOGLYCEMIC AGENTS; IMMEDIATE-EARLY PROTEINS; INSULIN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MATRIX METALLOPROTEINASES; NATRIURETIC PEPTIDE, BRAIN; ORGAN SIZE; PPAR GAMMA; RATS; RATS, INBRED SHR; RATS, INBRED WKY; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; THIAZOLIDINEDIONES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 35348836050     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.863     Document Type: Article

References (41)

1. Wakatsuki T, Schlessinger J, Elson EL: The biochemical response of the heart to hypertension and exercise. Trends Biochem Sci 2004; 29: 609-617.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
3. Sabbah HN, Sharov VG, Lesch M, Goldstein S: Progression of heart failure: a role for interstitial fibrosis. Mol Cell Biochem 1995; 147: 29-34.
4. Kai H, Kuwahara F, Tokuda K, Imaizumi T: Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 2005; 28: 483-490.
5. Asai T, Kushiro T, Fujita H, Kanmatsuse K: Different effects on inhibition of cardiac hypertrophy in spontaneously hypertensive rats by monotherapy and combination therapy of adrenergic receptor antagonists and/or the angiotensin II type 1 receptor blocker under comparable blood pressure reduction. Hypertens Res 2005; 28: 79-87.
6. Eghbali M, Weber KT: Collagen and the myocardium: fibrillar structure, biosynthesis and degradation in relation to hypertrophy and its regression. Mol Cell Biochem 1990; 96: 1-14.
7. Murdoch CE, Zhang M, Cave AC, Shah AM: NADPH oxidase-dependent redox signaling in cardiac hypertrophy, remodeling and failure. Cardiovasc Res 2006; 71: 208-215.
8. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527-550.
9. Kiec-Wilk B, Dembinska-Kiec A, Olszanecka A, Bodzioch M, Kawecka-Jaszcz K: The selected pathophysiological aspects of PPARs activation. J Physiol Pharmacol 2005; 56: 149-162.
10. Schoonjans K, Staels B, Auwerx J: The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302: 93-109.
11. Villarreal FJ, Asbun J: Peroxisome proliferator-activated receptors ligands, oxidative stress, and cardiac fibroblast extracellular matrix turnover. Hypertension 2004; 44: 621-622.
12. Kelly DP: PPARs of the heart: three is a crowd. Circ Res 2003; 92: 482-484.
13. Asakawa M, Takano H, Nagai T, et al: Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002; 105: 1240-1246.
14. Yamamoto K, Ohki R, Lee RT, Ikeda U, Shimada K: Peroxisome proliferator-activated receptor-gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation 2001; 104: 1670-1675.
15. Sakai S, Miyauchi T, Irukayama-Tomobe Y, Ogata T, Goto K, Yamaguchi I: Peroxisome proliferator-activated receptor-gamma activators inhibit endothelin-1-related cardiac hypertrophy in rats. Clin Sci 2002; 103: 16-20.
16. Ishibashi M, Egashira K, Hiasa K, et al: Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40: 687-693.
17. Shiomi T, Tsutsui H, Hayashidani S, et al: Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106: 3126-3132.
18. Iglarz M, Touyz RM, Viel EC, et al: Peroxisome proliferator-activated receptor-α and receptor-γ activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. Hypertension 2003; 42: 737-743.
19. Lygate CA, Hulbert K, Monfared M, Cole MA, Clarke K, Neubauer S: The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res 2003; 58: 632-637.
20. Frantz S, Hu K, Widder J, et al: Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol 2004; 141: 9-14.
21. Diep QN, Amiri F, Benkirane K, Paradis P, Schiffrin EL: Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats. Can J Physiol Pharmacol 2004; 82: 976-985.
22. Ide T, Tsutsui H, Kinugawa S, et al: Direct evidence for increased hydroxyl radicals originating from superoxide in the failing myocardium. Circ Res 2000; 86: 152-157.
23. Okhawa H, Ohishi N, Yagi N: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358.
24. Diep QN, El Mabrouk M, Cohn JS, et al: Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 105: 2296-2302.
25. Tokudome T, Horio T, Yoshihara F, et al: Direct effects of high glucose and insulin on protein synthesis in cultured cardiac myocytes and DNA and collagen synthesis in cardiac fibroblasts. Metabolism 2004; 53: 710-715.
26. Horio T, Suzuki M, Suzuki K, et al: Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 2005; 18: 949-957.
27. Spinale FG: Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002; 90: 520-530.
28. Fujii T, Onohara N, Maruyama Y, et al: Gα12/13-mediated production of reactive oxygen species is critical for angiotensin receptor-induced NFAT activation in cardiac fibroblasts. J Biol Chem 2005; 280: 23041-23047.
29. Grotendorst GR, Rahmanie H, Duncan MR: Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. FASEB J 2004; 18: 469-479.
30. Grotendorst GR, Okochi H, Hayashi N: A novel transforming growth factor β response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 1996; 7: 469-480.
31. Duncan MR, Frazier KS, Abramson S, et al: Connective tissue growth factor mediates transforming growth factor β-induced collagen synthesis: down-regulation by cAMP. FASEB J 1999; 13: 1774-1786.
32. Finckenberg P, Inkinen K, Ahonen J, et al: Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. Am J Pathol 2003; 163: 355-366.
33. Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M: Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-β-independent mechanism. Circulation 2005; 111: 2509-2517.
34. Rosenkranz S: TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004; 63: 423-432.
35. Schiffrin EL: Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am J Physiol Heart Circ Physiol 2005; 288: 1037-1043.
36. Zafiriou S, Stanners SR, Saad S, Polhill TS, Poronnik P, Pollock CA: Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts. J Am Soc Nephrol 2005; 16: 638-645.
37. Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, Hart CM: Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 2005; 288: 899-905.
38. Mehta JL, Hu B, Chen J, Li D: Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol 2003; 23: 2203-2208.
39. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL: Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 2004; 43: 48-56.
40. Chen K, Chen J, Li D, Zhang X, Mehta JL: Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension 2004; 44: 655-661.
41. Nesto RW, Bell D, Borrow RO, et al: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-2948.